7KDV image
Deposition Date 2020-10-09
Release Date 2021-03-17
Last Version Date 2024-11-13
Entry Detail
PDB ID:
7KDV
Keywords:
Title:
Murine core lysosomal multienzyme complex (LMC) composed of acid beta-galactosidase (GLB1) and protective protein cathepsin A (PPCA, CTSA)
Biological Source:
Source Organism:
Mus musculus (Taxon ID: 10090)
Host Organism:
Method Details:
Experimental Method:
Resolution:
4.59 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Beta-galactosidase
Gene (Uniprot):Glb1
Mutations:R468Q, N517D, E534G
Chain IDs:A, C, E, G, I, K
Chain Length:630
Number of Molecules:6
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Molecule:Lysosomal protective protein
Gene (Uniprot):Ctsa
Mutations:C32A
Chain IDs:B, D, F, H, J, L
Chain Length:461
Number of Molecules:6
Biological Source:Mus musculus
Ligand Molecules
Primary Citation
Structure of the murine lysosomal multienzyme complex core.
Sci Adv 7 ? ? (2021)
PMID: 33980489 DOI: 10.1126/sciadv.abf4155

Abstact

The enzymes β-galactosidase (GLB1) and neuraminidase 1 (NEU1; sialidase 1) participate in the degradation of glycoproteins and glycolipids in the lysosome. To remain active and stable, they associate with PPCA [protective protein cathepsin A (CTSA)] into a high-molecular weight lysosomal multienzyme complex (LMC), of which several forms exist. Genetic defects in these three proteins cause the lysosomal storage diseases GM1-gangliosidosis/mucopolysaccharidosis IV type B, sialidosis, and galactosialidosis, respectively. To better understand the interactions between these enzymes, we determined the three-dimensional structure of the murine LMC core. This 0.8-MDa complex is composed of three GLB1 dimers and three CTSA dimers, adopting a triangular architecture maintained through six copies of a unique GLB1-CTSA polar interface. Mutations in this contact surface that occur in GM1-gangliosidosis prevent formation of the LMC in vitro. These findings may facilitate development of therapies for lysosomal storage disorders.

Legend

Protein

Chemical

Disease

Primary Citation of related structures